TB-219 / Therabest - LARVOL DELTA

A novel dual chemokine receptor-expressing CD19 CAR-iPSC-derived NK cells (TB-219) to enhance cancer homing and therapeutic efficacy (AACR 2025) - "The advanced engineering of TB-219 incorporates significant improvements in persistence, cancer homing, and immune evasion, positioning it as a highly promising therapeutic candidate for CD19-positive hematological malignancies. The observed improvements in cytotoxicity, targeting, and survival in preclinical models suggest TB-219 may provide a durable and efficacious treatment option. These findings warrant further clinical investigation, positioning TB-219 as a potent and accessible NK cell therapy for patients with limited therapeutic options."

Clinical • Hematological Malignancies • Leukemia • Oncology • CCR7 • CD19 • CXCR4